In recent conversations with experts in epilepsy, the impact of stigmatization remains high for patients and ongoing efforts by clinicians to address this issue in the clinical setting has been underscored, despite the global lack of awareness about new treatments and other resources.
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders and oncology, will present data on cenobamate at the American Epilepsy Society (AES) Annual Meeting, to be held December 1-5, 2023, in Orlando, Florida.
CORAL GABLES, Fla., Aug. 14, 2023 Catalyst Pharmaceuticals, Inc. , a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel. -Today at 08:06 am- MarketScreener
/PRNewswire/ Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 75th American Epilepsy.